{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:51:04Z","timestamp":1772121064732,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jhep.2015.09.024","type":"journal-article","created":{"date-parts":[[2015,10,16]],"date-time":"2015-10-16T21:37:18Z","timestamp":1445031438000},"page":"292-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection"],"prefix":"10.1016","volume":"64","author":[{"given":"Stefan","family":"Zeuzem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"H\u00e9zode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Loustaud-Ratti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Gea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Olveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tivadar","family":"Banyai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Tarek","family":"Al-Assi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Gadano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Pruitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mih\u00e1ly","family":"Makara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Beumont-Mauviel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivi","family":"Ouwerkerk-Mahadevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"McPhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navdeep","family":"Boparai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kin","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Noviello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.09.024_b0005","unstructured":"World Health Organization. Hepatitis C key facts. April 2014. WHO factsheet 164. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. (Accessed on August 20, 2014)."},{"key":"10.1016\/j.jhep.2015.09.024_b0010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.024_b0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.024_b0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.024_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1478-3231.2011.02537.x","article-title":"The global health burden of hepatitis C virus infection","volume":"31","author":"Negro","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.09.024_b0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","article-title":"A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel","volume":"31","author":"Cornberg","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.09.024_b0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","article-title":"A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt","volume":"31","author":"Sievert","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.09.024_b0040","unstructured":"Food and Drug Administration. Sovaldi (sofosbuvir) [prescribing information], 2014."},{"key":"10.1016\/j.jhep.2015.09.024_b0045","unstructured":"European Medicines Agency. Sovaldi (sofosbuvir) summary of product characteristics, 2014."},{"key":"10.1016\/j.jhep.2015.09.024_b0050","unstructured":"Food and Drug Administration. Olysio (simeprevir) [prescribing information], 2013."},{"key":"10.1016\/j.jhep.2015.09.024_b0055","unstructured":"European Medicines Agency. Olysio (simeprevir) [summary of product characteristics], 2014."},{"key":"10.1016\/j.jhep.2015.09.024_b0060","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www hcvguidelines org\/full-report-view. (Accessed April 21, 2015 Accessed April 21, 2015)."},{"key":"10.1016\/j.jhep.2015.09.024_b0065","unstructured":"European Medicines Agency. Daklinza (daclatasvir) [summary of product characteristics], 2014."},{"key":"10.1016\/j.jhep.2015.09.024_b0070","unstructured":"Food and Drug Administration. Harvoni (ledipasvir and sofosbuvir) [prescribing information], 2014."},{"key":"10.1016\/j.jhep.2015.09.024_b0075","unstructured":"European Medicines Agency. Harvoni (ledipasvir and sofosbuvir) [summary of product characteristics], 2014."},{"key":"10.1016\/j.jhep.2015.09.024_b0080","unstructured":"Food and Drug Administration. VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information], 2014."},{"key":"10.1016\/j.jhep.2015.09.024_b0085","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(14)60065-9","article-title":"Efficacy and safety of the all-oral regimen of MK-5172\/MK-8752 +\/\u2212 ribavirin for 12 weeks in GT1 HCV\/HIV coinfected patients: The C-WORTHY study [Abstract]","volume":"60","author":"Sulkowski","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.024_b0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.024_b0095","article-title":"All oral fixed-dose combination sofosbuvir\/ledipasvir with or without ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study","volume":"O164","author":"Mangia","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.024_b0100","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.09.024_b0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.0006-341X.2002.00048.x","article-title":"Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials","volume":"58","author":"Lunceford","year":"2002","journal-title":"Biometrics"},{"key":"10.1016\/j.jhep.2015.09.024_b0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.09.024_b0115","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.024_b0120","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV Genotype 1 Infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.024_b0125","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.024_b0130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.024_b0135","unstructured":"Food and Drug Administration. Copegus (ribavirin) label 2012; 2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021511s020lbl.pdf. Accessed on August 20, 2014."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815006728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815006728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T04:39:09Z","timestamp":1565411949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815006728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0168827815006728"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.09.024","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725844072.793510383","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}